Trial reportJournal of diabetes and its complications
The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study.
Trial report in Journal of diabetes and its complications. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02129231. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ezetimibe/Simvastatin and Rosuvastatin for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy: a Randomized, Double Blinded, Placebo Controlled Clinical Trial
Open the trial in the graphEfficacy of Ubiquinone and Combined Antioxidant Therapy on Progression, Oxidative Stress Markers and Mitochondrial Dysfunction in Non-proliferative Diabetic Retinopathy: A Phase 2a Randomized Double-blind Placebo-controlled Study
Effect of Coenzyme Q10 (COQ10) on Chemotherapeutic Toxicity in Cancer Patients
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- The effect of CoQ10 supplementation on cardiovascular risk factors in patients with prediabetes and type 2 diabetes mellitus: a grade-assessed systematic review and dose-response meta-analysis.BMC pharmacology & toxicology · 2026Pooled it
- Effects of Coenzyme Q10 on Lipid, Glycemic, and Inflammatory Markers in Metabolic Disorders: A Systematic Review and Meta-Analysis.Journal of diabetes research · 2026Pooled it
- Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis.BMC neurology · 2021Pooled it
- The Role of Oxidative Stress in Peripheral Neuropathy.Journal of molecular neuroscience : MN · 2020Pooled it
- Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial.European journal of clinical pharmacology · 2022Trial
- The effect of ubiquinone and combined antioxidant therapy on oxidative stress markers in non-proliferative diabetic retinopathy: A phase IIa, randomized, double-blind, and placebo-controlled study.Redox report : communications in free radical research · 2016Trial
- Immunomodulation through Nutrition Should Be a Key Trend in Type 2 Diabetes Treatment.International journal of molecular sciences · 2024Review
- The effect of coenzyme Q10 supplementation on liver enzymes: A systematic review and meta-analysis of randomized clinical trials.Food science & nutrition · 2023Review
- Oxidative Stress in Diabetic Peripheral Neuropathy: Pathway and Mechanism-Based Treatment.Molecular neurobiology · 2023Review
- Natural products targeting inflammation-related metabolic disorders: A comprehensive review.Heliyon · 2023Review
- Coenzyme Q10 and Endocrine Disorders: An Overview.Antioxidants (Basel, Switzerland) · 2023Review
- Combined Supplementation of Coenzyme QNutrients · 2022Review
- Effects of coenzyme Q10 supplementation on glycemic control: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.EClinicalMedicine · 2022Article
- Diabetes: how to manage diabetic peripheral neuropathy.Drugs in context · 2022Review
- Antioxidant and Oxidative Stress: A Mutual Interplay in Age-Related Diseases.Frontiers in pharmacology · 2018Review
- Effects of coenzyme QDiabetes, metabolic syndrome and obesity : targets and therapy · 2018Article
- Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function.Journal of diabetes research · 2016Review
- Coenzyme q10 therapy.Molecular syndromology · 2014Article
- Combined therapeutic effects of low power laser (980nm) and CoQ10 on Neuropathic Pain in adult male rat.Medical journal of the Islamic Republic of Iran · 2014Article
- Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes model.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetic polyneuropathy aetiology is based on oxidative stress generation due to production of reactive oxygen species. Ubiquinone is reduced to ubiquinol and redistributed into lipoproteins, possibly to protect them from oxidation.
aimsTo evaluate the impact of oral ubiquinone in diabetic polyneuropathy, and the role of lipid peroxidation (LPO) and nerve growth factor (NGF-β).
methodsWe conducted a double-blind, placebo-controlled clinical trial, patients were randomized to ubiquinone (400 mg) or placebo daily for 12 weeks. Main outcomes were clinical scores, nerve conduction studies, LPO, NGF-β and safety.
resultsTwenty four patients on experimental group and twenty five on control group met the inclusion criteria (mean age 56 years, 22% male and 78% female, mean evolution of type 2 diabetes mellitus 10.7 years). Significant improvement on experimental vs control group was found in neuropathy symptoms score (from 2.5 ± 0.7 to 1 ± 0.8, p<0.001), neuropathy impairment score (5.5 ± 4 to 3.1 ± 2.6, p<0.001), sural sensory nerve amplitude (13.0 ± 6.1 to 15.8 ± 5.1 μV, p=0.049), peroneal motor nerve conduction velocity (39.7 ± 5.0 to 47.8 ± 4.9 m/s, p=0.047), and ulnar motor nerve conduction velocity (48.8 ± 6.8 to 54.5 ± 6.1m/s, p=0.046). There was a significant reduction of LPO in subjects treated with ubiquinone vs placebo (16.7 ± 8.6 and 23.2 ± 15.8 nmol/mL, respectively) with p<0.05, and NGF-β did not change (control 66.5 ± 26.7 vs. experimental 66.8 ± 28.4 pg/mL, p=0.856). No drug-related adverse reactions were reported.
conclusionsTwelve weeks treatment with ubiquinone improves clinical outcomes and nerve conduction parameters of diabetic polyneuropathy; furthermore, it reduces oxidative stress without significant adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.